U.S. stock futures mixed; Nvidia earnings spark little cheer
In a recent transaction, Newton Charles W., the Chief Financial Officer of Lyell Immunopharma , Inc. (NASDAQ:LYEL), acquired 200,000 shares of the company’s common stock. The shares were purchased at a weighted average price of $0.5581, amounting to a total value of approximately $111,620. The purchase comes as the stock trades near its 52-week low, having declined over 76% in the past year. According to InvestingPro analysis, the stock appears undervalued at current levels. The transaction, which took place on March 17, 2025, was conducted through The Charles & Lisa Newton Living Trust, where Newton serves as co-grantor and co-trustee. This acquisition increases Newton’s indirect ownership to 200,000 shares, while his direct ownership stands at 172,725 shares following the transaction.
In other recent news, Lyell Immunopharma has received a notice from Nasdaq regarding non-compliance with the minimum bid price requirement, as its stock has closed below $1.00 for 33 consecutive business days. The company has until July 22, 2025, to rectify this issue, with options including a potential reverse stock split to meet the minimum bid price rule. Failure to comply could lead to delisting, although an extension may be granted if the company meets other listing standards. Meanwhile, H.C. Wainwright has maintained a Neutral rating on Lyell Immunopharma, with a price target of $1.00, citing ongoing developments in the company’s IMPT-314 CAR-T therapy. The firm is particularly interested in upcoming data from trials in the second-line setting, expected by mid-2025. Analysts at H.C. Wainwright have noted the competitive landscape for CAR-T therapies and the challenges Lyell Immunopharma faces in demonstrating substantial superiority over existing treatments. The company’s efforts to address Nasdaq compliance are being closely monitored by investors, with the potential for significant implications if the requirements are not met.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.